Form 4: ADMA Biologics CFO Reports Routine Stock Withholding for Tax Purposes

ADMA Biologics' CFO and Treasurer, Brad L. Tade, reported a disposition of 7,123 shares of common stock, representing a routine tax withholding upon the vesting of restricted stock units.

Summary

• Brad L. Tade, CFO and Treasurer of ADMA Biologics, Inc., reported a disposition of 7,123 shares of common stock on July 24, 2025.
• This transaction was not an open market sale but represented shares withheld by ADMA Biologics to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units (RSUs).
• The shares were valued at $17.31 per share for the purpose of this withholding.
• Following this transaction, Mr. Tade directly beneficially owns 239,419 shares of common stock.
• This total includes 62,227 unvested RSUs granted on February 19, 2025; 54,300 unvested RSUs granted on July 24, 2024; 37,500 unvested RSUs granted on February 26, 2024; and 50,000 unvested RSUs granted on June 26, 2023.
• All unvested RSUs vest quarterly on each annual anniversary of their grant date over four years, subject to Mr. Tade's continued service.
• The beneficial ownership also includes 35,392 shares acquired through open market purchases and previous RSU vestings after tax withholding.

Sentiment

Score: 5

Explanation: The filing is neutral as it reports a routine, non-discretionary transaction related to executive compensation (tax withholding upon RSU vesting) and does not indicate any operational or financial changes for the company.

Positives

• Continued significant beneficial ownership by a key executive, including a substantial number of unvested Restricted Stock Units (RSUs), aligns management's interests with long-term shareholder value.
• The reported transaction was a routine tax withholding event, not a discretionary sale, indicating no change in investment sentiment from the executive.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction related to executive compensation. The continued significant beneficial ownership by the CFO aligns his interests with shareholders.
• Employees: No direct impact indicated by this filing.
• Customers: No direct impact indicated by this filing.
• Suppliers: No direct impact indicated by this filing.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Continued vesting of unvested Restricted Stock Units (RSUs) for Brad L. Tade over the next four years, contingent on his continued service.

Key Dates

Keywords

ADMA Biologics, Form 4, Insider Transaction, Restricted Stock Units, RSU, Executive Compensation, Brad L. Tade, Stock Withholding, Beneficial Ownership